|
| 37531956 | Small molecule targeting of transcription-replication conflict for selective chemotherapy. | | 2023 |
| 36367377 | Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. | Oncologist | 2023 |
| 37673892 | A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. | Nat Commun | 2023 |
| 37839499 | A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. | | 2023 |
| 37745372 | Inhibiting Stromal Class I HDACs Curbs Pancreatic Cancer Progression. | bioRxiv | 2023 |
| 37805542 | Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer. | | 2023 |
| 37802055 | Single-cell mapping identifies MSI<sup>+</sup> cells as a common origin for diverse subtypes of pancreatic cancer. | Cancer Cell | 2023 |
| 37720027 | Tumor Response to Stroma-Modifying Therapy: Magnetic Resonance Imaging Findings in Early-Phase Clinical Trials of Pegvorhyaluronidase alpha (PEGPH20). | | 2023 |
| 38057326 | Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. | Nat Commun | 2023 |
| 36900085 | Can Imaging Using Radiomics and Fat Fraction Analysis Detect Early Tissue Changes on Historical CT Scans in the Regions of the Pancreas Gland That Subsequently Develop Adenocarcinoma? | | 2023 |
| 37119937 | Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. | | 2023 |
| 35136485 | GZ17-6.02 and axitinib interact to kill renal carcinoma cells. | Oncotarget | 2022 |
| 36372388 | Effect of acoustic cluster therapy (ACT®) combined with chemotherapy in a patient-derived xenograft mouse model of pancreatic cancer. | Journal of Controlled Release | 2022 |
| 35819261 | Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. | Cancer Res | 2022 |
| 35425930 | Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. | Med | 2022 |
| 35535581 | A phase II trial of the super-enhancer inhibitor Minnelideâ¿¢ in advanced refractory adenosquamous carcinoma of the pancreas. | Future Oncol | 2022 |
| 35850192 | An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. | Gastroenterology | 2022 |
| 36614019 | Increasing Stress to Induce Apoptosis in Pancreatic Cancer via the Unfolded Protein Response (UPR). | | 2022 |
| 32362152 | A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses. | | 2022 |
| 32398486 | Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. | Annals of Surgery | 2022 |
| 34108669 | CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. | Cancer Gene Therapy | 2022 |
| 34132691 | Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma. | Ann Surg | 2022 |
| 35276694 | Mechanisms of GZ17-6.02 resistance. | Anti-Cancer Drugs | 2022 |
| 35035775 | GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells. | Oncotarget | 2022 |
| 34762841 | Natural chalcones elicit formation of specialized pro-resolving mediators and related 15-lipoxygenase products in human macrophages. | Biochemical Pharmacology | 2022 |
| 35074270 | Corrigendum to "Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma" [Semin. Cancer Biol. 75 (2021) 153-168]. | Seminars in Cancer Biology | 2022 |
| 35305109 | In Reply. | Oncologist | 2022 |
| 34490108 | GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins. | Frontiers in Oncology | 2021 |
| 34077739 | Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib. | Biochemical Pharmacology | 2021 |
| 33898322 | GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. | Front Oncol | 2021 |
| 34223403 | Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer. | Med | 2021 |
| 33937087 | Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells Autophagy and Death Receptor Signaling. | Frontiers in Oncology | 2021 |
| 33597261 | Analysis of recurrently protected genomic regions in cell-free DNA found in urine. | Science Translational Medicine | 2021 |
| 34312215 | A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. | Clin Cancer Res | 2021 |
| 33345430 | Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer. | Oncologist | 2021 |
| 33215270 | A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. | Cancer Chemotherapy and Pharmacology | 2021 |
| 33049362 | Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma. | Seminars in Cancer Biology | 2021 |
| 34465601 | EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers. | Clinical Cancer Research | 2021 |
| 34568010 | Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. | Frontiers in Oncology | 2021 |
| 34848876 | Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. | Nature | 2021 |
| 31391296 | An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. | Oncologist | 2020 |
| 36738075 | Circulating levels of hydroxylated bradykinin function as an indicator of tissue HIF-1α expression. | | 2020 |
| 31912905 | Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling. | Journal of Cellular Physiology | 2020 |
| 31857726 | Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. | Br J Cancer | 2020 |
| 31911180 | Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. | Cellular Signalling | 2020 |
| 32314268 | Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. | Targeted Oncology | 2020 |
| 31951027 | GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy. | Journal of Cellular Physiology | 2020 |
| 31580386 | Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. | JAMA Oncology | 2020 |
| 32451495 | BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. | Nat Med | 2020 |
| 32032721 | Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. | Journal of the American College of Surgeons | 2020 |